Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Sexually Transmitted Infections01:26

Sexually Transmitted Infections

Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
Principles of Disease Surveillance01:26

Principles of Disease Surveillance

Disease surveillance is the systematic collection, analysis, and interpretation of health data essential to the planning, implementation, and evaluation of public health practice. This process integrates data dissemination to entities responsible for preventing and controlling disease, injury, and disability. Surveillance systems provide crucial information for action, helping public health authorities make informed decisions to manage and prevent outbreaks, ensure public safety, optimize...
Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From Research to Impact: Assessing a Decade of CDC's Public Health Science by Topic Area, 2014-2023.

Public health reports (Washington, D.C. : 1974)·2026
Same author

Notes from the Field: Outbreak of Ebola Disease Caused by Bundibugyo Virus - Democratic Republic of the Congo and Uganda, May 2026.

MMWR. Morbidity and mortality weekly report·2026
Same author

Stenotrophomonas maltophilia Bloodstream Infection Outbreak in Acute Care Hospital, California, USA, 2022-2023<sup>1</sup>.

Emerging infectious diseases·2026
Same author

Understanding the role of overdose witnesses: responses and characteristics of people who inject drugs in Oakland and San Francisco.

Harm reduction journal·2026
Same author

Hepatitis C virus genotype 4 cluster with suspected sexual transmission in Chicago, IL.

BMC public health·2025
Same author

The future of survey research with the world's sexual or gender minority youth.

The Lancet. Child & adolescent health·2025

Related Experiment Video

Updated: May 26, 2026

Use of Interferon-&gamma; Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

HPV vaccine implementation in STD clinics--STD Surveillance Network.

Elissa Meites1, Eloisa Llata, Susan Hariri

  • 1Division of STD Prevention, CDC, Atlanta, GA 30333, USA. emeites@cdc.gov

Sexually Transmitted Diseases
|December 21, 2011
PubMed
Summary

Few US public STD clinics offer the human papillomavirus (HPV) vaccine, despite experience with other immunizations. Key barriers include vaccine cost, staff time, and follow-up challenges.

More Related Videos

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
06:57

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Published on: June 14, 2019

Related Experiment Videos

Last Updated: May 26, 2026

Use of Interferon-&gamma; Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
06:57

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Published on: June 14, 2019

Area of Science:

  • Public Health
  • Vaccinology
  • Epidemiology

Background:

  • The human papillomavirus (HPV) vaccine is crucial for preventing HPV-related cancers and sexually transmitted infections.
  • Public health clinics play a vital role in vaccine accessibility and disease prevention.

Purpose of the Study:

  • To assess the availability and uptake of the HPV vaccine in US public sexually transmitted disease (STD) clinics.
  • To identify barriers hindering HPV vaccine implementation in these settings.

Main Methods:

  • A survey was distributed to selected public STD clinics across the United States.
  • Data collected included vaccine availability, target populations, funding, and reported barriers.

Main Results:

  • Only 17% (7 of 42) of surveyed clinics offered the HPV vaccine, despite most having experience with other vaccines.
  • Commonly cited barriers included vaccine cost, required staff time for administration, and difficulties with patient follow-up.

Conclusions:

  • Significant gaps exist in HPV vaccine provision within US public STD clinics.
  • Addressing financial, logistical, and staffing barriers is essential to improve HPV vaccine accessibility and coverage in these critical public health settings.